Company intelligence / Profile preview
Prolong Pharmaceuticals
South Plainfield, New Jersey, United Statesprolongpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Prolong’s lead candidate, PP‑007 (Sanguinate®, a PEGylated carboxyhemoglobin bovine), has demonstrated safety in over twelve completed clinical trials involving more than three hundred patients across various hypoxic/ischemic conditions. The product recently received FDA Fast Track designation for acute ischemic stroke. Early data suggest benefits in improving blood flow, reducing inflammation, and increasing survival in severe anemia and trauma settings. No products are yet approved.
- Therapeutic areas
- HematologyCardiovascular
- Modalities
- PEGylated large molecules (e.g., PEGylated carboxyhemoglobin)Recombinant proteinsPeptidesColony-stimulating factors (historically)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Prolong Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prolong Pharmaceuticals.